Recro Pharma, Inc. (REPH): Price and Financial Metrics
REPH Price/Volume Stats
| Current price | $2.09 | 52-week high | $3.79 |
| Prev. close | $2.10 | 52-week low | $1.38 |
| Day low | $2.00 | Volume | 141,800 |
| Day high | $2.14 | Avg. volume | 126,298 |
| 50-day MA | $1.71 | Dividend yield | N/A |
| 200-day MA | $1.89 | Market Cap | 117.93M |
REPH Stock Price Chart Interactive Chart >
Recro Pharma, Inc. (REPH) Company Bio
Recro Pharma is a clinical stage specialty pharmaceutical company, engaging in developing non-opioid therapeutics for the treatment of pain. The company was founded in 2007 and is based in Malvern, Pennsylvania.
Latest REPH News From Around the Web
Below are the latest news stories about Recro Pharma Inc that investors may wish to consider to help them evaluate REPH as an investment opportunity.
Recro Reports Progress Towards Launching Fill/Finish and Lyophilization Capabilities at San Diego FacilityFull Scope of New Service Capabilities to be Operational in Q2; Company Has Already Secured Project Commitments from Multiple New ClientsSAN DIEGO, Calif. and GAINESVILLE, Ga., Feb. 23, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today reported key progress in adding fill/finish and lyophil |
Recro to Report Financial Results for Fourth Quarter and Year-end 2021 on March 1, 2022Conference Call and Webcast Scheduled for Tuesday, March 1, 2022 at 4:30 p.m. EasternSAN DIEGO and GAINESVILLE, Ga., Feb. 22, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASDAQ: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that the company will release financial results for the fourth quarter and year-end 2021 after the market |
Recro Pharma (NASDAQ:REPH) investors are sitting on a loss of 80% if they invested three years agoAs every investor would know, not every swing hits the sweet spot. But really big losses can really drag down an... |
Frontier Wealth Management LLC Buys Rio Tinto PLC, T-Mobile US Inc, Raytheon Technologies Corp, ...Kansas City, MO, based Investment company Frontier Wealth Management LLC (Current Portfolio) buys Rio Tinto PLC, T-Mobile US Inc, Raytheon Technologies Corp, Recro Pharma Inc, New Relic Inc, sells Goldman Sachs Just Us Large Cap Equity ETF, Invesco BulletShares 2021 Corporate Bond ETF, United Parcel Service Inc, MGP Ingredients Inc, Silvergate Capital Corp during the 3-months ended 2021Q4, according to the most recent filings of the investment company, Frontier Wealth Management LLC. |
Recro Wins $1.5 Million Formulation Development and CGMP Manufacturing Contract to Support Clinical Development of Topical Treatment for Skin Cancer PreventionSAN DIEGO, and GAINESVILLE, Ga., Jan. 26, 2022 (GLOBE NEWSWIRE) -- Recro Pharma, Inc. (“Recro”; NASD: REPH), a contract development and manufacturing organization (CDMO) dedicated to solving complex formulation and manufacturing challenges primarily in small molecule therapeutic development, today announced that it has been awarded a new formulation development and cGMP manufacturing contract from a key department of the United States government. The contract focuses on supporting clinical devel |
REPH Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | -57.78% |
| 5-year | -60.57% |
| YTD | N/A |
| 2022 | 0.00% |
| 2021 | -40.00% |
| 2020 | -84.45% |
| 2019 | 158.17% |
| 2018 | -23.24% |
Continue Researching REPH
Want to see what other sources are saying about Recro Pharma Inc's financials and stock price? Try the links below:Recro Pharma Inc (REPH) Stock Price | Nasdaq
Recro Pharma Inc (REPH) Stock Quote, History and News - Yahoo Finance
Recro Pharma Inc (REPH) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...